Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$36.71

-1.61 (-4.20%)

16:22
11/06/18
11/06
16:22
11/06/18
16:22

Myriad Genetics sees Q2 adj. EPS 36c-38c, consensus 43c

Sees Q2 revenue $216M-$218M, consensus $224.5M.

  • 06

    Nov

  • 06

    Nov

  • 14

    Nov

MYGN Myriad Genetics
$36.71

-1.61 (-4.20%)

10/10/18
PIPR
10/10/18
UPGRADE
Target $53
PIPR
Overweight
Myriad Genetics upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Myriad Genetics to Overweight and raised his price target for the shares to $53 from $38. After updating his reimbursement model for Myriad's Prolaris, Vectra, and GeneSight, the analyst believes the company has $9 of earnings per share power. Quirk now has increased confidence in Myriad's ability to beat Street expectations and admits he's been wrong on the shares.
11/01/18
PIPR
11/01/18
NO CHANGE
Target $53
PIPR
Overweight
Myriad Genetics should be bought on weakness, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Myriad Genetics' shares are off about 15% on two items, neither of which he believes will have a lasting effect on the company's business. First is an FDA safety communication about genetics tests used to predict drug response, he points out, adding that the letter "has teeth," but likely for consumer-oriented tests. The second is the 23&Me approval for a consumer-based pharmacogenomics test, which could certainly open up more testing, but within the consumer-driven, not physician-driven channel, he argues. Accordingly, Quirk recommends buying shares on the pullback, and reiterates an Overweight rating and $53 price target on the stock.
11/01/18
MSCO
11/01/18
NO CHANGE
MSCO
Myriad Genetics shares defended at Morgan Stanley
11/01/18
MSCO
11/01/18
NO CHANGE
MSCO
Overweight
Morgan Stanley says Myriad selloff on 23andMe approval a buying opportunity
Morgan Stanley analyst Steve Beuchaw said today's move lower in shares of Myriad Genetics "reflects confusion" on the regulatory backdrop for enetic tests and he believes the fact that 23andMe received an FDA approval yesterday for a consumer-facing pharmacogenetic screen is actually a positive for Myriad. Direct-to-consumer tests are not a substitute for clinical lab tests, as noted by the FDA, said Beuchaw, who believes uptake of consumer genomic tests, including their promotion by 23andMe, is a tailwind for Myriad and the category. He views the pullback as a buying opportunity and keeps an Overweight rating on Myriad Genetics shares.

TODAY'S FREE FLY STORIES

CRUS

Cirrus Logic

$40.00

0.85 (2.17%)

08:48
02/19/19
02/19
08:48
02/19/19
08:48
Conference/Events
Cirrus Logic management to meet with Cowen »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

ECL

Ecolab

$163.45

1.82 (1.13%)

08:47
02/19/19
02/19
08:47
02/19/19
08:47
Earnings
Ecolab reports Q4 adj. EPS $1.54, consensus $1.54 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 28

    May

ORTX

Orchard Therapeutics

$15.08

0.58 (4.00%)

08:47
02/19/19
02/19
08:47
02/19/19
08:47
Conference/Events
Orchard Therapeutics management to meet with Cowen »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GSK

GlaxoSmithKline

$41.24

0.38 (0.93%)

08:46
02/19/19
02/19
08:46
02/19/19
08:46
Conference/Events
GlaxoSmithKline management to meet with Cowen »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 18

    May

GMDA

Gamida Cell

$13.25

0.3 (2.32%)

, EDIT

Editas Medicine

$20.09

0.22 (1.11%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Hot Stocks
Gamida Cell, Editas Medicine announce agreement to evaluate use of CRISPR tech »

Gamida Cell (GMDA)…

GMDA

Gamida Cell

$13.25

0.3 (2.32%)

EDIT

Editas Medicine

$20.09

0.22 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EXPD

Expeditors

$73.56

-0.45 (-0.61%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Earnings
Expeditors reports Q4 EPS $1.02, consensus 85c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPO

Midstates Petroleum

$9.25

-0.17 (-1.80%)

, AXDX

Accelerate Diagnostics

$19.82

0.65 (3.39%)

08:45
02/19/19
02/19
08:45
02/19/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

MPO

Midstates Petroleum

$9.25

-0.17 (-1.80%)

AXDX

Accelerate Diagnostics

$19.82

0.65 (3.39%)

WATT

Energous

$8.91

0.11 (1.25%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

NIO

NIO Inc.

$7.41

-0.07 (-0.94%)

EPD

Enterprise Products

$28.21

0.01 (0.04%)

NBEV

New Age Beverages

$6.50

-0.08 (-1.22%)

ITB

iShares U.S. Home Construction ETF

$35.22

0.36 (1.03%)

CWH

Camping World

$15.11

-0.105 (-0.69%)

SAND

Sandstorm Gold

$5.49

0.06 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 22

    Feb

  • 27

    Feb

  • 04

    Mar

WBC

Wabco

$116.78

0.19 (0.16%)

08:44
02/19/19
02/19
08:44
02/19/19
08:44
Recommendations
Wabco analyst commentary  »

Baird would be aggressive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$3.80

0.28 (7.95%)

08:43
02/19/19
02/19
08:43
02/19/19
08:43
Conference/Events
Adverum Biotechnologies management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 27

    Feb

DPZ

Domino's Pizza

$281.63

-5.46 (-1.90%)

08:43
02/19/19
02/19
08:43
02/19/19
08:43
Recommendations
Domino's Pizza analyst commentary  »

Domino's Pizza price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 14

    Mar

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Conference/Events
UBS pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

GVA

Granite Construction

$45.48

0.59 (1.31%)

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Hot Stocks
Granite's Water and Mineral Services Group awarded $22.5M in sewer projects »

Granite announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

WWW

Wolverine World Wide

$39.54

0.94 (2.44%)

08:42
02/19/19
02/19
08:42
02/19/19
08:42
Recommendations
Wolverine World Wide analyst commentary  »

Fresh Pick designation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MCEP

Mid-Con Energy

$0.98

0.06 (6.52%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Hot Stocks
Mid-Con Energy sell Texas properties for $60M, buys Oklahoma assets for $27.5M »

Mid-Con Energy, through…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$16.95

(0.00%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Recommendations
Kratos Defense analyst commentary  »

Kratos Defense price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEP

PepsiCo

$115.89

3.4 (3.02%)

, KO

Coca-Cola

$45.25

-0.345 (-0.76%)

08:41
02/19/19
02/19
08:41
02/19/19
08:41
Upgrade
PepsiCo, Coca-Cola rating change  »

Macquarie upgrades…

PEP

PepsiCo

$115.89

3.4 (3.02%)

KO

Coca-Cola

$45.25

-0.345 (-0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 03

    Mar

  • 18

    May

HMST

HomeStreet

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Recommendations
HomeStreet analyst commentary  »

HomeStreet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$62.38

0.03 (0.05%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Recommendations
Henry Schein analyst commentary  »

Henry Schein price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GPC

Genuine Parts

$107.49

1.7447 (1.65%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Hot Stocks
Breaking Hot Stocks news story on Genuine Parts »

Genuine Parts sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Apr

AEO

American Eagle

$20.07

-0.03 (-0.15%)

08:39
02/19/19
02/19
08:39
02/19/19
08:39
Hot Stocks
American Eagle announces license agreement to expand brands to Europe »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GPC

Genuine Parts

$107.49

1.7447 (1.65%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Hot Stocks
Genuine Parts reports Q4 sales for Automotive Group up 11.4% »

Fourth quarter sales for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Apr

CHFS

CHF Solutions

$10.05

0.75 (8.06%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Hot Stocks
CHF Solutions enters South American market with Bragenix distribution agreement »

CHF Solutions announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

MRVL

Marvell

$18.82

-0.37 (-1.93%)

08:37
02/19/19
02/19
08:37
02/19/19
08:37
Upgrade
Marvell rating change  »

Marvell upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

GPL

Great Panther Silver

$0.80

0.0576 (7.76%)

08:36
02/19/19
02/19
08:36
02/19/19
08:36
Hot Stocks
Great Panther Silver announces court approval for acquisition of Beadell »

Great Panther Silver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

NUVA

NuVasive

$58.65

0.12 (0.21%)

08:36
02/19/19
02/19
08:36
02/19/19
08:36
Hot Stocks
NuVasive receives FDA 510(k) clearance for Precice Bone Transport System »

NuVasive announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.